Atlanta, GA – Scibility Media – 11/11/2014.
DexCom, Inc. (NASDAQ:DXCM) stock continues to register an impressive rally in the market on the heels of gaining FDA approval on a new algorithm for the G4 Platinum Continuous Glucose Monitoring system. FDA approval for DexCom’s system will go a long way in enhancing blood glucose monitoring making it comparable to finger stick meters.
Accurate CGM System
DexCom is looking to enhance its dominance in the blood glucose monitoring space with the FDA approval as G4 Platinum system approaches Mean Absolute Relative difference. At the moment, DexCom, Inc. (NASDAQ:DXCM)’s system is the first and only CGM system that is single-digit MARD enabled. G4 Platinum is already considered the most accurate CGM system in the market today.
DexCom plans to use the innovation to accord healthcare providers as well as patients and caregivers a complete picture of glucose activity in the body. The management team remains buoyant that the new system has the potential to replace traditional finger sticks. G4 Platinum CGM system continues to be an important source of revenue for DexCom, Inc. (NASDAQ:DXCM) driving superior product revenue growth over the years. Since the launch of the system, the company’s revenue has grown by 63%.
Growth in Revenue
In the third quarter, DexCom reported a 60% rise in product revenue as the system continues to gain traction in the medical space at the back of growth in customer base. As the system continues to be accepted in the medical space, DexCom hopes it will offset a net loss of 8 cents a share that was posted in the third quarter. The company is enjoying an impressive run on the revenue front having soared by 60.8% in the quarter to a high of $69 million.
G4 Platinum is not the only product that DexCom is relying on for revenue but it is also enjoying success with first approved FDA mobile monitoring DexCom SHARE that transmits glucose levels wirelessly and can be accessed in smartphones.
Success will depend on how the company performs against competition, mostly coming from Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) going forward.
InfuSystem Holdings Inc. (NYSEMKT:INFU) reported impressive third quarter earnings that it attributes’ to successful implementation of an IT strategy that seeks to transform the way business is done. CEO, Eric Steen, has reiterated that the company continues to grow on key business areas of rentals equipment sales, as well as service and sales of disposable products.
Impact of Higher Penetration Levels
InfuSystem Holdings Inc. (NYSEMKT:INFU) is already focusing on the future having made an investment of $3.7 million towards the pump fleet segment that aims at accelerating growth going forward. Revenues for the third quarter soared by 6% and 11% for the nine months ending September 30, 2014. InfuSystem Holdings Inc. (NYSEMKT:INFU) attributes the increase in revenue to an increase in net additional rental and sales customers as well as higher penetration levels in the existing rental and sales customer accounts.
InfuSystem Holdings continues to record a higher mix of Medicaid and payment payors in the rental business. Mr. Stern has emphasized that InfuSystem Holdings Inc. (NYSEMKT:INFU) remains committed to building a competitive advantage in the space that is sure to generate more shareholder value going forward. The company has already built 25 new oncology infusion centers equipped with full electronic medical records
Patient Satisfaction Scores
Mr. Stern has also confirmed that the definitive CMS ruling on non-competitive bid areas will not have any impact on the company’s earnings heading into 2015. The company remains optimistic that a focus on operational and IT improvements, as well as ongoing improvements on commercial contracts, will have a huge bearing on the company’s performance as of 2016. High patient-satisfaction scores continue to be the driving force behind InfuSystem Holdings Inc. (NYSEMKT:INFU) according to the CEO.
Increase in selling and marketing expenses to $2.5 million from $2.4 million is not of concern considering gross profit continues to grow reaching highs of $11.7 million, an increase of 3%. A decrease in cash at hand to $4.2 million from $4.8 million as of last year has been attributed to ongoing changes in accounts payable as well as other accruals.
Medical Alarm Concepts Holdings Inc. (OTCMKTS: MDHI) To Air MediPendant Ad 200-Times in November
Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) is pushing to have its patented emergency personal medical device become a mainstream name with the announcement that it will be airing a 2 minute commercial ad on Cablevisions News 12. The ad is to air 200 times in the month of November as the company seeks to bolster sales.
The ad specifically targets the elder population which is expected to grow by 57% in Connecticut by 2040. 50% of the audiences being targeted by the ad have an average income of $75,000 while 30.7% have an average income of $35,000. The ad is to be aired on News 12 Connecticut and News 12 Westchester.
Elderly Population Driving Innovation
Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) hopes an increase in elderly technology will increase the demand of its patented technology. The aging population in the U.S is expected to be a major driver of technology innovation and spending in the years to come. The company has already confirmed that plans are underway to further product innovation in the space as well as accelerate corporate growth.
In a recent filing with the SEC, Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) affirmed it had reached reporting status and now plans to enhance timely outreach to existing shareholders.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.